Topic
Middle East Research
Geopolitical tensions in the Middle East, specifically involving the Iran war and the lack of confidence in US-Iran diplomatic deals, continue to exert significant influence over global financial markets. These regional dynamics have sustained elevated oil prices and placed upward pressure on sovereign bond yields, creating an environment of 'jaded cynicism' among investors. While the resulting inflationary concerns have triggered a sell-off in government bonds, researchers suggest this represents a tactical entry point into quality, intermediate-maturity assets as recessionary risks from high energy costs may be underestimated. In equity markets, the macro backdrop is facilitating a rotation into early-cycle industrials and materials, even as business investment elsewhere cools due to widespread policy uncertainty. Furthermore, tactical research highlights specific conviction ideas in aerospace and diversified industrials as potentially resilient hedges against regional volatility. Ultimately, the confluence of high energy prices and extreme hedge fund positioning in other regions makes the Middle East a critical focal point for monitoring global inflationary trajectories.
4813 reports available
All reports
Page 201 of 201
The New Inflation Regime
TS Lombard · Apr 23, 2026
Equity Positioning and Key Levels
Goldman Sachs · Apr 13, 2026
Investment Strategy Quarterly
Raymond James · Apr 1, 2026
March and Q1 2026 Performance Review
Deutsche Bank · Apr 1, 2026
Markets and Macro
Goldman Sachs · Mar 29, 2026
Good Morning Mail
Goldman Sachs · Mar 25, 2026
Sentiment Positioning Late Cycle Tightening and Long Term Oil
Goldman Sachs International · Mar 14, 2026
Global Equities Call
Goldman Sachs · Mar 10, 2026
From Geopolitical Shocks To Structural Repricing
UBS · Mar 1, 2026
TMT Special Sales: Nvidia and Indra Beat, WPP Strategy, and Tech Conference Wrap
Goldman Sachs · Feb 26, 2026
Tactical Short: Expensive Defensives and Staples
Goldman Sachs & Co. LLC · Feb 20, 2026
When Tangible Wins
Goldman Sachs · Feb 20, 2026
Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals
William Blair · Jan 8, 2026